Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Liposomal Doxorubicin Market: By Product: Doxil/Caelyx, Lipodox, Myocet, Others; By Application: Leukaemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Other Cancers; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Liposomal Doxorubicin Market Outlook
The global liposomal doxorubicin market attained a value of more than USD 1,100 million in 2021. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 6.1% to reach over USD 1,569 million by 2027.
The Rising Prevalence of Ovarian Cancer is Driving the Growth of the Market
The global market for liposomal doxorubicin is expanding owing to an increase in breast and ovarian cancer cases in recent years. In addition to this, the market growth can also be ascribed to an increased awareness of the advantages of liposomal doxorubicin formulations over standard doxorubicin. Despite advances in technology and research, cancer claimed the lives of several people in 2008.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The treatment of breast cancer, thyroid cancer, and pancreatic cancer have all seen substantial advancements in technology and drugs/vaccines, resulting in higher survival rates. Liposomal doxorubicin is one of a new family of medication formulations that are administered in liposomes, which are small vesicles which has taken over the market lately, thereby pushing the market growth.
North America is Expected to Hold a Significant Share in the Overall Market
North America is projected to account for a substantial percentage of global revenue in the market. This can be attributed to the high prevalence of ovarian, breast, and liver cancers, as well as a number of other malignancies in the region. Furthermore, the region's growth is fuelled by the existence of superior healthcare facilities and newer medications such as liposomal doxorubicin. Moreover, high level of patient awareness of the many therapies available in the market is another factor, which boosts the market growth in the region. The market growth in North America is further positively influenced by the robust reimbursement and regulatory framework.
Liposomal Doxorubicin: Definition and Segmentation
Liposomal doxorubicin is an anti-cancer chemotherapy drug. Also known by the brand names Caelyx or Myocet, liposomal doxorubicin is used for the treatment of different cancers, including breast cancer, ovarian cancer, and gastric cancer, among others.
Based on product, the market can be divided into:
- Doxil/Caelyx
- Lipodox
- Myocet
- Others
The market can be broadly categorised on the basis of its application as:
- Leukaemia
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Gastric Cancer
- Liver Cancer
- Kidney Cancer
- Multiple Myeloma
- Ovarian Cancer
- Other Cancers
The EMR report looks into the regional markets of liposomal doxorubicin like North America, Europe, the Asia Pacific, the Middle East Africa, and Latin America.
Rapid Cases of Breast Carcinoma is Expected to Boost the Market Growth
Breast cancer has been rising at an alarming rate across various countries, which makes liposomal doxorubicin one of its major applications. One of the primary aspects boosting the drug's popularity and usage to treat breast cancer is the growing innovation in formulations. These are some of the factors furthering the growth of the market. In addition, some of the drivers expected to propel the market in the coming years are increased use of chemotherapy treatments, rising demand for targeted therapy drugs, and increased investment by private firms to cater to this application. Furthermore, government funding towards the healthcare sector is also one of the important factors for widening the market’s reach globally.
Key Industry Players in the Global Liposomal Doxorubicin Market
The report presents a detailed analysis of the following key players in the global liposomal doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Pfizer, Inc
- Sun Pharmaceutical Industries Ltd.
- Cipla, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Janssen Products, LP
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2021 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Application, Region |
| Breakup by Product | Doxil/Caelyx, Lipodox, Myocet, Others |
| Breakup by Application | Leukaemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Liver Cancer, Kidney Cancer, Multiple Myeloma, Ovarian Cancer, Other Cancers |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd., Janssen Products, LP, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Liposomal Doxorubicin Market Analysis
8.1 Key Industry Highlights
8.2 Global Liposomal Doxorubicin Historical Market (2017-2021)
8.3 Global Liposomal Doxorubicin Market Forecast (2022-2027)
8.4 Global Liposomal Doxorubicin Market by Product
8.4.1 Doxil/Caelyx
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Lipodox
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Myocet
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Liposomal Doxorubicin Market by Application
8.5.1 Leukaemia
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Bone Sarcoma
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Breast Cancer
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Endometrial Cancer
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Gastric Cancer
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2017-2021)
8.5.5.3 Forecast Trend (2022-2027)
8.5.6 Liver Cancer
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2017-2021)
8.5.6.3 Forecast Trend (2022-2027)
8.5.7 Kidney Cancer
8.5.7.1 Market Share
8.5.7.2 Historical Trend (2017-2021)
8.5.7.3 Forecast Trend (2022-2027)
8.5.8 Multiple Myeloma
8.5.8.1 Market Share
8.5.8.2 Historical Trend (2017-2021)
8.5.8.3 Forecast Trend (2022-2027)
8.5.9 Ovarian Cancer
8.5.9.1 Market Share
8.5.9.2 Historical Trend (2017-2021)
8.5.9.3 Forecast Trend (2022-2027)
8.5.10 Other Cancers
8.6 Global Liposomal Doxorubicin Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Pfizer, Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Sun Pharmaceutical Industries Ltd.
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Cipla, Inc.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Teva Pharmaceuticals Industries Ltd.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Janssen Products, LP
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Liposomal Doxorubicin Market: Key Industry Highlights, 2017 and 2027
2. Global Liposomal Doxorubicin Historical Market: Breakup by Product (USD Million), 2017-2021
3. Global Liposomal Doxorubicin Market Forecast: Breakup by Product (USD Million), 2022-2027
4. Global Liposomal Doxorubicin Historical Market: Breakup by Application (USD Million), 2017-2021
5. Global Liposomal Doxorubicin Market Forecast: Breakup by Application (USD Million), 2022-2027
6. Global Liposomal Doxorubicin Historical Market: Breakup by Region (USD Million), 2017-2021
7. Global Liposomal Doxorubicin Market Forecast: Breakup by Region (USD Million), 2022-2027
8. North America Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2017-2021
9. North America Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Europe Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2017-2021
11. Europe Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Asia Pacific Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2017-2021
13. Asia Pacific Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Latin America Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2017-2021
15. Latin America Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Middle East and Africa Global Liposomal Doxorubicin Historical Market: Breakup by Country (USD Million), 2017-2021
17. Middle East and Africa Global Liposomal Doxorubicin Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Global Liposomal Doxorubicin Market Structure
Key Questions Answered in the Report
The global liposomal doxorubicin market attained a value of more than USD 1,100 million in 2021.
The market is projected to grow at a CAGR of 6.1% between 2022 and 2027.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach over USD 1,569 million by 2027.
The increase in breast and ovarian cancer cases, as well as increased awareness of the advantages of liposomal doxorubicin formulations over standard doxorubicin has been aiding the market growth.
The market is expected to be defined by the ongoing technological advancements in the industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different products available in the market are doxil/caelyx, lipodox, and myocet, among others.
The different applications of liposomal doxorubicin include leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, and ovarian cancer, among other cancers.
The major players in the industry are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd, and Janssen Products, LP, among others.
Analyst Review
The global liposomal doxorubicin market attained a value of more than USD 1,100 million in 2021, driven by the increase in breast and ovarian cancer cases, as well as increased awareness of the advantages of liposomal doxorubicin formulations. The market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 6.1%. The market is projected to reach over USD 1,569 million by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its product type, the liposomal doxorubicin industry can be segmented into doxil/caelyx, lipodox, and myocet, among others. On the basis of its application, the industry is divided into leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, and ovarian cancer, among other cancers. The major regional markets for liposomal doxorubicin are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Cipla, Inc., Teva Pharmaceuticals Industries Ltd, and Janssen Products, LP, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global oral antibiotics market attained a value of over USD 18,365.8 million in 2021, driven by the extensive use of oral antibiotics for the treatment of infectious diseases. Aided by the growing...
The Asia Pacific vaccine market attained a value of nearly USD 3.92 billion in 2021, driven by the robust growth of the healthcare sector. Aided by the increasing research and development (R&D) activi...
The global microencapsulation market attained a value of about USD 9.52 billion in 2021, driven by the advancements in the pharmaceutical and nutraceutical industries. Aided by growing inclination tow...
The global anti-infectives market attained a value of about USD 118.36 billion in 2021, driven by the rising prevalence of infectious diseases. Aided by large scale investments into the pharmaceutical...
The global infertility drugs market is being driven by the rising cases of infertility among men and women. Aided by the rising investments to develop advanced infertility treatment laboratories, the ...
NEWSLETTER